OncoSec Medical Inc (ONCSQ)

[hschlauch]

Very smart move in my opinion. Dilutive? Yes. But the percentage will ultimately depend on market valuation. How valuable is a product that may rescue anti-pd-1 nonresponders in advanced metastatic melanoma and perhaps triple negative breast cancer? Only approximately 5% of advanced TNBC patients observe responses to anti-pd-1 treatments. Both are significant unmet needs, no doubt about it. There are basically no other options for these patients once they fail anti-pd-1 treatments. This reminds me of the early days with checkpoint inhibitors - the momentum will grow pretty quick in my opinion.